Since MARCO is conserved between humans and mice, we hypothesize that targeting MARCO in humans could remodel the suppressive environment and reduce the anti-tumor responses to increase the efficacy of immunotherapy in PDAC. The gene discussed is MARCO; the disease is neoplasm.